Please assess the completion status of the following clinical trial:

Trial Title: Combined N-of-1 Trials Mexiletine vs Placebo in Patients With Non-Dystrophic Myotonia (NDM)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. At least 18 years of age~2. Genetically confirmed diagnosis of NDMs~3. Participation in the Genetical variability of the Non-dystrophic Myotonia study of J. Trip or a new patient with genetically confirmed NDM.~Exclusion Criteria:~1. Inability or unwillingness to provide informed consent.~2. Other neurological conditions that might affect the assessment of the study measurements.~3. Genetic confirmed Myotonic Dystrophy type 1 (DM1) (CTG \> 50 repeats), or Myotonic Dystrophy type 2 (DM2).~4. Patients with existing cardiac conduction defects, evidenced on ECG including but not limited to the following conditions: malignant arrhythmia or cardiac conduction disturbances (such as second degree AV block, third degree atrio-ventricular (AV) block, or prolonged QT interval \>500 ms or QRS duration \> 150 msec).~5. Current use of the following antiarrhythmic medication for a cardiac disorder:flecainide acetate, encainide, disopyramide, procainamide, quinidine, propafenone or mexiletine.~6. Women who are pregnant or lactating.~7. Patients currently on medications for myotonia such as phenytoin and flecainide acetate within 5 days of enrollment, carbamazepine and mexiletine within 3 days of enrollment, or propafenone, procainamide, disopyramide, quinidine and encainide within 2 days of enrollment.~8. Patients with renal or hepatic disease, heart failure, history of myocardial infarction, or seizure disorders.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo tablets three times daily orally
- Mexiletine (Type: ACTIVE_COMPARATOR): Mexiletine 200mg three times daily orally

Based on this trial design, predict the completion outcome and termination type (if applicable).